Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000248083 | SCV000307401 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Eurofins Ntd Llc |
RCV000725702 | SCV000338739 | uncertain significance | not provided | 2016-01-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000725702 | SCV000523700 | likely benign | not provided | 2021-03-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001080324 | SCV000640888 | likely benign | Nemaline myopathy 2 | 2025-01-28 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000248083 | SCV002766159 | uncertain significance | not specified | 2024-09-27 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.9071C>T (p.Ala3024Val) results in a non-conservative amino acid change in the encoded protein sequence. Three of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0012 in 246034 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in NEB causing Nemaline Myopathy 2 (0.0012 vs 0.0035), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.9071C>T in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 257836). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Ce |
RCV000725702 | SCV004154153 | likely benign | not provided | 2025-02-01 | criteria provided, single submitter | clinical testing | NEB: BP4 |
Natera, |
RCV001080324 | SCV001454968 | uncertain significance | Nemaline myopathy 2 | 2019-11-11 | no assertion criteria provided | clinical testing |